Ninah Schultz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

14 April 2021, 10:00 pm EDT By The "Adenovirus" ingredient found in COVID-19 vaccines from Johnson &Johnson (J&J) and AstraZeneca has been one of the top talks of the town as it causes alarm and a dangerous side effect. The use of the virus is to help the delivery and effectiveness of a vaccine as it enters the human body, making people immune to the disease to fight against it. (Photo : Screenshot From @DiarioDeTabasco From Twitter) In the recent developments of the coronavirus pandemic, vaccines from Pfizer and BioNTech, and Moderna have been released for Emergency Use Authorization (EUA...

Apr 14, 2021 TUESDAY, April 13, 2021 (HealthDay News) — While rare, thrombosis and thrombocytopenia can occur after the ChAdOx1 nCoV-19 adenoviral vector vaccine against COVID-19 (AstraZeneca), according to two reports published online April 9 in the New England Journal of Medicine. Andreas Greinacher, M.D., from Universitätsmedizin Greifswald in Germany, and colleagues assessed the clinical and laboratory features of 11 patients (nine women; median age, 36 years) in Germany and Austria experiencing thrombosis or thrombocytopenia after vaccination with ChAdOx1 nCov-19. Thrombotic events o...

April 09, 2021 One of the first papers to document the rare thrombotic events seen in Austria and Germany involving a form of thrombocytopenia after inoculation with the vaccine jointly developed by the University of Oxford and AstraZeneca has now been published in the New England Journal of Medicine, accompanied by a brief report confirming similar findings in a Norwegian cohort. Taken together the papers show a clear link between this particular vaccine and the ”clotting abnormalities” that have led countries around the world to pause or revise their plans for the use of the Oxford/As...

email article Following up on previous reviews of the evidence, the European Medicines Agency (EMA), WHO, and Britain's Medicine's and Healthcare Products Regulatory Agency (MHRA) have issued statements saying that the overall benefits continue to outweigh the risks of very rare blood clots with low platelets reported after the AstraZeneca COVID-19 vaccine. The WHO now states that a causal relationship is "considered plausible but is not confirmed," while the MHRA has said that the evidence is now "stronger" for a link between the vaccine and these events. The EMA calls these "unusual b...